Background Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia, and can reduce inpatient stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment of schizophrenia in Germany. Objective To estimate, based on a previously published model, the cost effectiveness of PLAI compared with other common antipsychotic treatment strategies in patients diagnosed with schizophrenia in Germany. Methods A Markov decision analytic model was adapted to the German healthcare system. The model considers the cost effectiveness for PLAI as a maintenance treatment for patients with schizophrenia from the payer perspective. The patients transition between eight health states on a monthly basis over a 5-year time horizon. As therapeutic strategies, PLAI, quetiapine, risperidone long-acting injections (RLAI), oral olanzapine, oral risperidone, zuclopenthixol decanoate, olanzapine long-acting injections (OLAI), oral typical and oral atypical were compared. Probability of relapse, level of adherence, side effects and treatment discontinuation were derived from the Swedish original model. Input factors regarding resource use and costs were estimated and adjusted for the German healthcare system. A probabilistic sensitivity analyses (PSA) using cost-effectiveness scatter plots was performed to visualize the robustness of the results. Results In base-case scenario, PLAI is superior to RLAI in gained quality-adjusted life-years (QALYs) and avoided relapses. Relative to all other treatment strategies, PLAI is more effective with regard to gained QALYs and avoided relapses but results in higher treatment costs over a 5-year horizon in base-case scenario. The results were tested in PSA. If a cost-effectiveness threshold of €30,000 is assumed, for example, PLAI can be considered to be cost effective compared with RLAI in about 92.5 % of cases regarding gained QALYs, and in 78.6 % of cases regarding avoided relapse. Compared with OLAI, in about 94.4 % of cases regarding gained QALYs and in 99.9 % of cases regarding avoided relapse, cost effectiveness can be considered. Comparing PLAI and zuclopenthixol decanoate, cost effectiveness can be assumed in about 90.4 % of cases regarding gained QALYs, and in all cases regarding avoided relapse. Conclusions PLAI dominates RLAI and compared with the other treatment strategies PLAI has shown to be more effective but results in higher costs in base-case scenario.
Key Points for Decision Makers
• Paliperidone long-acting injectable (PLAI), a oncemonthly LAI antipsychotic, was approved for treatment of schizophrenia in Germany • PLAI is more effective with regard to gained qualityadjusted life-years and avoided relapses but results in higher costs in base-case scenario
Background
Schizophrenia is a serious illness with considerable economic impact. The annual incidence is about 19 cases per 100,000 in Germany [1] . Because of the specific characteristics of the illness, e.g. frequent relapses in the course of the disease leading to hospital stays and often resulting in premature retirement due to disability, schizophrenia is considered to be one of the most costly mental disorders [2] . According to official cost data compiled by the Federal Office of Statistics, schizophrenia (ICD F20) resulted in direct costs of around €2.0 billion to the statutory health insurance in 2008 in Germany [3] . On top of this, there are considerably high indirect costs to be taken into account which, at present, are not recorded or evaluated in any routine statistics in the form of monetary values [4] [5] [6] [7] . However, official statistics for 2008 indicate as a proxy variable for indirect costs that as a result of this disease, in total 86,000 years of employment were lost in Germany [3] . Both the low age at which patients experience their first episode of the underlying disease (approximately between 18 and 35 years) and the episodic relapses in the illness course contribute to this outcome [8] .
Studies have identified hospital stays as being the most important cost driver [2, 5, 7, [9] [10] [11] [12] . Frequent inpatient stays can disrupt social and occupational integration. As a result of the associated loss of working ability and social participation, the individual's quality of life is severely limited. Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia and can reduce inpatient stays. Antipsychotics can be subdivided into conventional first-generation antipsychotics (FGA) and atypical second-generation antipsychotics (SGA). Conventional and atypical long-acting injectables (LAIs) can be an alternative to oral antipsychotics requiring daily adherence for treatment efficacy. Adherence levels are usually low among schizophrenia patients [13, 14] . Clinical evidence suggests that LAIs improve patient's adherence and eventually reduce hospital stays [15] [16] [17] [18] [19] . Recently, the longacting atypical antipsychotic paliperidone LAI (PLAI), a once-monthly LAI antipsychotic, was approved for the treatment of schizophrenia in Germany. Paliperidone is the primary active metabolite of risperidone which has been available since the early 1990s in Germany as an oral SGA. For risperidone LAI (RLAI), several cost-effectiveness studies demonstrated economic superiority when compared with other LAIs and oral antipsychotics. Examples include Spain [20, 21] , Sweden [22] and France [18] . In a framework of clinical studies, it could be shown that the switch to RLAI has led to a significant decrease of overall treatment costs in Germany [23, 24] .
When it comes to PLAI, some cost-effectiveness models suggest that PLAI has advantages compared with other LAIs, including RLAI, in terms of cost effectiveness. This result has been shown for Greece [25] , Norway [26] , Sweden [27] and Korea [28] . In contrast to these models, we implemented several oral antipsychotic treatment arms in our current model as in most countries the prescription rate of LAI antipsychotics out of all antipsychotics prescribed for the treatment of schizophrenia does not exceed 20 % and is in fact most often considerably lower [29] [30] [31] . Cost effectiveness of PLAI in the US is contingent on the adherence level of oral medications. PLAI is cost effective, if oral atypical antipsychotic adherence is below a threshold rate of 44.9 % [32] .
The aim of this study is to estimate the cost effectiveness of PLAI compared with the other common antipsychotic treatment strategies. Our cost-effectiveness model is the first attempt to assess the cost effectiveness of PLAI in patients with schizophrenia in Germany.
Methods

Model Structure and Design
A Markov decision analytic model was adapted to the German healthcare system. The original model was programmed in Microsoft Excel 2007 supplemented by Visual Basic Application programming. In-depth details about the structure of the original model and related limitations should be taken from the publication of Mehnert et al. [27] as well as from Table A1 in the electronic supplementary material (ESM). The model considers the cost effectiveness for PLAI as a maintenance treatment for patients with schizophrenia from a payer perspective. The patients transition between different health states on a monthly basis over a 5-year time horizon (Fig. 1) . The model has eight states for every line of treatment. Six of these states are stable health states with different levels of adherence and presence/absence of adverse events (AEs) and two are relapse health states, requiring or not requiring hospitalisation. Directions of transition between health states and treatment lines are indicated by arrows. Finally, death is a terminal model state.
The model accommodates four subsequent treatment lines, with eight possible health states for every line of treatment. Based on expert opinion, the second-line treatments consist of a mix of antipsychotic treatments, which are independent upon the first-line treatment given ( Table 1 ). The second-line treatments include four options with which the patients can be treated (split between treatments to add up to 100 %). The third and last line of treatment was assumed to be clozapine. Expert opinion was elicited from five medical specialists in schizophrenia using the Delphi method. Experts were recruited from inpatient as well as outpatient settings from rural and urban regions in north and south Germany.
The incremental cost-effectiveness ratio (ICER) was calculated on the basis of incremental costs and effects. Effects are expressed as quality-adjusted life-years (QALYs) and avoided relapse. The ratio of difference in costs of PLAI compared with the alternatives was divided by the difference in effects. Hence, the additional cost per additional unit of effect was computed for PLAI compared with all of the other common antipsychotic treatment strategies.
Utility data for different health states were obtained from a study eliciting values using a time trade-off instrument administrated by interview of stable patients with schizophrenia in the UK [33] . Utility scores represent the healthrelated quality of life (HRQoL) associated with specific health states on a scale from zero (death) to one (perfect health). The utility scores were multiplied by the cumulative time spend in each health state to provide an estimate of QALYs. The presence of common side effects relating to antipsychotic medication were taken into account.
Resource Use and Unit Costs
Resource use and unit costs were adjusted for the German healthcare system. The resource use is accumulated based on the time spent in different health states. The mean daily doses for drug treatment were taken from the original model. For PLAI, the mean daily dose was assumed to be 2.5 mg/day (Table 2 ). Information about unit costs was derived from Lauer-Taxe, which is an electronic German drug information system [34] . According to the current recommendations for the valuation of resources the price of the largest package size was chosen [35, 36] . For patented drugs the price of the original package, and for not-patented drugs the package with the lowest price, was utilized. As reference date, the middle of the year 2011 was chosen (1 July). From the perspective of the statutory health insurance discounts as well as additional payments of the patients are not relevant. Therefore, discounts of the pharmacy and the manufacturer, as well as additional payments of the patients, were removed. For outpatient care the assumption was that all specialist visits are remunerated by the quarterly standard service volume (Regelleistungsvolumen) and quality-related additional volume (qualitätsgebundenes Zusatzvolumen). Therefore, for every Association of Statutory Health Insurance Physicians (Kassenärztliche Vereinigung) the standard and additional remunerations were obtained [37] . With this approach, 13 out of the 17 Associations of Statutory Health Insurance Physicians had their standard compensation quarterly standard service volume assessed for this study. In contrast, the mean quality-linked additional volume was not available. The mean costs were adjusted for the distribution of the German population by weighting them with the number of residents in the different federal states in 2011 [38] . Additionally, the costs were weighted by the distribution of psychiatrists and neurologists in Germany. For this purpose the number of psychiatrists was assumed to be 3,500 and the number of neurologists was assumed to be 2,250 [39] . Costs per contact were calculated to be €24.58 (Table 3) . Based on expert opinion, 80 % of the patients were stable and 20 % were relapse patients not requiring hospitalization. For stable patients, 1.5 specialist contacts per quarter, and for relapse patients 6 specialist contacts per quarter, were assumed by expert opinion. This corresponds to 0.5 contacts per month for stable patients and 2 contacts per month for relapse patients (Table 4 ). Stable patients with side effects were assumed to have a 25 % additional contact rate for specialist contacts, which means an additional 0.125 contacts per month.
The contact rate for primary care physicians was taken from the original model. This was 0.3 per month for stable patients and 0.267 per month for relapse patients not requiring hospitalization. The costs per contact were taken from Braun et al. [40] and adjusted for the year 2011. For adjustment the consumer price index of the Federal Statistical Office (Destatis) was chosen for the particular year [41] . Costs per contact were calculated to be €32.02.
For occupational therapy the contact rate was assumed by expert opinion to be at an average of one contact per month per patient. The costs per contact were elected from the official price list of the Association of Statutory Health Insurance Physicians in Westfalen-Lippe, which was €43.00 in 2011 [42] . In Germany the costs for visits to the psychiatric institute outpatient department (PIA) in many cases were reimbursed by a quarterly flat charge. The mean fee was estimated by Melchinger (2008) to be €250 per quarter, which correspondents to €83.33 per month [43] . In Germany, 21.3 % of schizophrenia patients are treated at psychiatric institute outpatient departments [44] . OLAI olanzapine long-acting injectable, PLAI paliperidone long-acting injectable, RLAI risperidone long-acting injectable [42, 43] Inpatient care costs vary between the different German federal states. Therefore, for every federal state the mean hospital charge per inpatient day was selected for the year 2009 and adjusted for 2011 by the consumer price index [45] . The population distribution was considered for the calculation of the nationwide mean hospital per diem charge [38] . Based on this information, a nationwide mean hospital per diem charge of €220.00 was calculated. The average length of stay in inpatient acute psychiatric wards was elected from the official inpatient diagnostic database of the Federal Statistical Office (Destatis) [46] . The most recently available information about the average length of stay for schizophrenia (ICD F20) was 33.7 days in 2010.
Discounting and Sensitivity Analysis
In the base-case analysis for costs and health effects a discount rate of 3 % was defined. To evaluate the effect of different discount rates for cost and effects on outcomes, a sensitivity analysis calculation was carried out using different discount rates.
The sensitivity of the base-case results to input parameters was explored by probabilistic sensitivity analyses (PSA). PSA on ICER were run using 1,000 simulations. Based on the incremental costs and effects generated by these sensitivity analyses, scatter plots were calculated. Parameters included in the PSA were the following (Table A2 in the ESM): ICER incremental cost-effectiveness ratio, OLAI olanzapine long-acting injectable, PLAI paliperidone long-acting injectable, QALY qualityadjusted life-years, RLAI risperidone long-acting injectable
• Probabilities of adherence, relapse and side effects by treatment • Effect of adherence on the probability of relapse • Probability of hospitalisation in case of relapse • Average duration of relapse and time spent in hospital • Health state utilities and utility decrement associated with side effects • Switch rates by reason • Inpatient unit costs
Results
Based on the model and input variables, patients receiving PLAI were associated with better outcomes (more QALYs and fewer relapses) over the 5-year time horizon than the other treatment strategies in base-case scenario ( Table 5 ). The overall total cost per treatment arm was largely attributed to antipsychotic acquisition costs and the cost of hospitalizations. Antipsychotic acquisition costs were highest for PLAI, RLAI and olanzapine LAI (OLAI). Hospitalisation cost was the highest for quetiapine, oral typical (haloperidol oral) and oral risperidone. Overall total costs were highest for RLAI, PLAI and OLAI.
As incremental cost-effectiveness measures, the cost per gained QALY and the cost per avoided relapse were calculated (Table 6 ). The ICER (€/gained QALY) of PLAI was the highest compared with oral atypical (€69,659) and oral risperidone (€37,320). Compared with OLAI and quetiapine, the ICER was the lowest (€748 and €14,151, Fig. 2 Cost-effectiveness plane, PLAI vs. RLAI. PLAI paliperidone long-acting injectable, QALY qualityadjusted life-years, RLAI risperidone long-acting injectable respectively). RLAI were dominated by PLAI regarding gained QALYs in base-case scenario.
The ICER per avoided relapse of PLAI was the highest compared with oral atypical (€13,318) and zuclopenthixol decanoate (€9,557). Compared with OLAI and quetiapine, the ICER was lowest (€278 and €793, respectively). RLAI were dominated by PLAI regarding avoided relapse in base-case scenario.
In line with the original model, the results of the sensitivity analyses confirmed the robustness of the model to variation in the input parameters. The sensitivity analyses have been conducted in comparison with the other LAIs, which were RLAI, OLAI and zuclopenthixol decanoate. The incremental costs and effects of the 1,000 runs per comparison were shown by scatter plots. A sensitivity analysis calculation using different discount rates is shown in Table A3 in the ESM.
The results of the PSA comparing the cost effectiveness of PLAI versus RLAI for gained QALYs and avoided relapses are presented in Fig. 2 . In 77.2 % of the simulations, PLAI dominates RLAI regarding gained QALYs. The cost-effectiveness plane of avoided relapse shows a linear relationship between PLAI and RLAI. The scatter plot appears symmetrical. Overall, 66.5 % points are represented as dominant. If a cost-effectiveness threshold of €30,000 is assumed for example, PLAI can be considered to be cost effective in about 92.5 % of cases regarding gained QALYs, and in 78.6 % of cases regarding avoided relapse (Fig. 3) .
Comparing PLAI and OLAI in 39.0 % of the simulations, PLAI dominates OLAI regarding gained QALYs (Fig. 4) . Conversely, OLAI dominates in 4.4 % of cases regarding gained QALYs. In 52.8 % of the simulations PLAI is associated with more gained QALYs and higher Fig. 3 Cost-effectiveness acceptability curves, PLAI vs. RLAI. PLAI paliperidone long-acting injectable, QALY quality-adjusted life-years, RLAI risperidone long-acting injectable costs. Regarding cost-effectiveness plane of avoided relapses in 42.9 % of the simulations, PLAI dominates OLAI. In all other simulations (57.0 %), except one case (0.1 %), PLAI is associated with more avoided relapses but higher costs. Assuming a cost-effectiveness threshold of €30,000 for example, PLAI can be considered to be cost effective in about 94.4 % of cases regarding gained QALYs and in 99.9 % of cases regarding avoided relapse (Fig. 5) .
Results of comparing the cost effectiveness of PLAI versus zuclopenthixol decanoate are presented in Fig. 6 . In all of the simulations, PLAI has gained more QALYs and avoided relapses but has shown higher costs. PLAI can be considered to be cost effective in about 90.4 % of cases regarding gained QALYs and in all cases (100.0 %) regarding avoided relapse if a cost-effectiveness threshold of €30,000 is assumed (Fig. 7) .
Discussion
To estimate the cost effectiveness of PLAI in the German treatment setting, a Markov decision analytic model was used. Treatment with PLAI over a 5-year time horizon was estimated to result in better outcomes but higher treatment costs when compared with the other treatment strategies.
The ICER of PLAI for gained QALYs was highest compared to oral atypical, oral risperidone and oral olanzapine. The ICER per avoided relapse was highest compared to oral atypical, zuclopenthixol decanoate and oral olanzapine. PLAI gained more QALYs and avoided more relapses over the 5-year time horizon than any other of the compared treatment strategies in base-case scenario.
There is an economic and clinical need to reduce the number of relapses. Patients with relapses incur 90 % higher costs than stable patients [47] . From a clinical Fig. 4 Cost-effectiveness plane, PLAI vs. OLAI. OLAI olanzapine long-acting injectable, PLAI paliperidone long-acting injectable, QALY quality-adjusted life-years perspective, the reduction of relapses is nevertheless a meaningful outcome of this model. In the long-term treatment of schizophrenia it has shown that with every suffered relapse the time it takes a patient to overcome the acute episode grows significantly [48] . Additionally, it is most often reportedly burdensome for both patients and their relatives to be readmitted to inpatient treatment, most often as a consequence from a relapse [49, 50] .
Importantly, already at an early stage in the illness course a relapse does impact later treatment response. Emsley and colleagues [51] were able to show that a considerable number of first-episode patients having responded well to initial treatment with an SGA LAI and having suffered a relapse following treatment discontinuation after 2 years did not reach the level of response they had experienced through antipsychotic treatment for their first episode. This is the first study estimating the cost effectiveness of PLAI for Germany. Compared with the previously published model for the Swedish healthcare setting, the cost effectiveness of PLAI is less due to the fact that Mehnert et al. [27] found PLAI to be economically dominant compared with OLAI and RLAI. PLAI was less costly and more effective than other treatment options in Sweden. A reason for this diverging result could be found in different levels of the mean hospital per diem charge and the average length of stay in inpatient acute psychiatric wards. For Germany, a mean hospital per diem charge of €220.00 was calculated, whereas for the Swedish model a per diem charge of SEK 6,112 was assumed (1 EUR = 8.68 SEK). Additionally, the average length of stay in inpatient acute psychiatric wards was assumed to be shorter in Germany (33.7 days) than in Sweden (66.4 days). Uncertainty and key drivers of the model results were explored for the previously published model by Mehnert et al. [27] . One-way deterministic sensitivity analyses and PSA were used for this purpose. The results were robust when tested in both approaches. Switch rates and level of adherence had a greater impact on relapses and costs, and side effects were found to have the greatest impact on the number of gained QALYs. The probabilistic sensitivity analysis after adaption of resources and costs for the German healthcare system has enabled us to keep into consideration the variability of main parameters of the model.
The limitations of the model have been described in detail by Mehnert et al. [27] . A limitation specific to the German healthcare system was that not all input factors were available by published data. The number of relapse patients not requiring hospitalisation, the number of specialist visits for stable and relapse patients, as well as the additional contact rate for specialist visits for stable patients experiencing side effects, had to be based on expert opinion to adapt the model according to the German treatment setting. Another limitation was that for outpatient care the quarterly standard service volume was only available for 13 of 17 Associations of Statutory Health Insurance Physicians and the quality-related additional volume was not available. A further limitation was that there is no information for the treatment patterns and costs for treatment in daytime clinics in Germany. Therefore, only the full inpatient treatment was considered for hospitalisations. Efficacy estimates for the class oral atypical, which consists of paliperidone oral, oral olanzapine and oral risperidone, were approximated by averaging evidence which could mask differences between them. However, results for oral olanzapine and risperidone were shown supplemental as discrete information which enables direct comparison to PLAI.
Indirect costs associated with work productivity losses were excluded from the analysis as the payer perspective was considered. However, including indirect costs would most likely result in higher cost effectiveness of PLAI due to the fact that it has less relapse time than other treatment strategies and this would reduce productivity losses.
This Markov model neglects several important clinical aspects, thus limiting the potential benefits and underestimating the potential disadvantages of the long-term Fig. 6 Cost-effectiveness plane, PLAI vs. zuclopenthixol decanoate. PLAI paliperidone long-acting injectable, QALY quality-adjusted life-years treatment of schizophrenia with an LAI antipsychotic. In recent publications, patients treated with an LAI reported their preference for an injectable because of increased convenience when compared with oral antipsychotics, and reliable efficacy in relapse prevention [52] . On the other hand, patients have reported that LAI treatment is coercive, causes pain at the injection site and limits flexibility in antipsychotic side effect management [52] [53] [54] . So, in addition to cost-effectiveness aspects targeted in the current model, numerous clinical factors, including the patient's individual preference, have to be taken into account when choosing between an oral and LAI antipsychotic for the long-term treatment of schizophrenia.
For the model mainly input parameters from clinical trials, official cost data sources as well as expert opinion were used. This is usual in traditional cost-effectiveness analyses which are used to compare alternative scenarios by synthesizing evidence from various sources and by extrapolating beyond data observed in clinical trials. The use of administrative health insurance claims data as input information for cost, relapse and compliance patterns could be an alternative to reflect real-world conditions of treatment [55, 56] . Future studies could evaluate the presented results based on health insurance claims data.
Conclusions
In base-case scenario, treatment with PLAI over a 5-year time-horizon was estimated to result in better outcomes and higher treatment costs. PLAI gained more QALYs and avoided more relapses in base case than any other of the compared treatment strategies. PLAI is superior to RLAI and, compared with most other treatment strategies, demonstrates reasonable cost effectiveness in base-case scenario. Contribution Jan Zeidler led the design of the study and was primarily responsible for collecting input parameters and calculating the model, as well as for drafting the article. He is guarantor for the overall content. Jörg Mahlich gave support in collecting input factors and drafting of the article. Wolfgang Greiner and Stephan Heres contributed to the conception and planning of the study, the definition and interpretation of input factors and drafting of the article for important intellectual content.
